Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)’. The study aims to evaluate the efficacy of combining tarlatamab with durvalumab compared to durvalumab alone in extending overall survival in patients with extensive-stage small-cell lung cancer (ES-SCLC).
The study tests two interventions: tarlatamab, an experimental drug administered bi-weekly, and durvalumab, an existing treatment given every four weeks. The combination aims to improve patient outcomes compared to durvalumab alone.
This randomized, open-label study employs a parallel intervention model with no masking, focusing on treatment as its primary purpose. Participants are allocated randomly to receive either the combination of tarlatamab and durvalumab or durvalumab alone.
The study began on June 5, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 25, 2025, indicating ongoing recruitment.
This study could significantly impact Amgen’s stock performance by potentially expanding its oncology portfolio, especially if results show improved patient outcomes. The competitive landscape in the oncology sector, particularly in lung cancer treatments, could see shifts depending on the study’s success.
The study is currently ongoing, with further details available on the ClinicalTrials portal.